Update: Praluent® Permanent Injunction Stay Extended to 45 Days

U.S. District Court Decisions

We reported last week that a permanent injunction against the sale of Praluent® (alirocumab) was issued in Amgen v. Sanofi/Regeneron.  The day after the court’s order, defendants filed a motion to stay the injunction while the decision is appealed to the Federal Circuit.

Yesterday, Judge Robinson denied defendants’ motion to stay, noting that in the order on the permanent injunction, “the court essentially weighed the [relevant] factors and entered a limited stay” by delaying the imposition of the permanent injunction by 30 days.  Although the court declined to grant defendants’ motion,  the original 30-day stay of the injunction was extended to 45 days in order “to provide ample opportunity for an appeal of the instant order.”

Download PDF

Comments are closed.